Abstract:Efficacy of clinical chemotherapeutic agents depends not only on direct cytostatic and cytotoxic effects but also involves in eliciting (re)activation of tumour immune effects. One way to provoke long-lasting antitumour immunity is coined as immunogenic cell death (ICD), exploiting the host immune system against tumour cells as a "second hit". Although metal-based antitumour complexes hold promise as potential chemotherapeutic agents, ruthenium (Ru)-based ICD inducers remain sparse. Herein, we report a half-sandwich complex Ru(II) bearing aryl-bis(imino) acenaphthene chelating ligand with ICD inducing properties for melanoma in vitro and in vivo. Complex Ru(II) displays strong anti-proliferative potency and potential cell migration inhibition against melanoma cell lines. Importantly, complex Ru(II) drives the multiple biochemical hallmarks of ICD in melanoma cells, i. e., the elevated expression of calreticulin (CRT), high mobility group box 1 (HMGB1), Hsp70 and secretion of ATP, followed by the decreased expression of phosphorylation of Stat3. In vivo the inhibition of tumour growth in prophylactic tumour vaccination model further confirms that mice with complex Ru(II)-treated dying cells lead to activate adaptive immune responses and anti-tumour immunity by the activation of ICD in melanoma cells. Mechanisms of action studies show that complex Ru(II)-induced ICD could be associated with mitochondrial damage, ER stress and impairment of metabolic status in melanoma cells. We believe that the half-sandwich complex Ru(II) as an ICD inducer in this work will help to design new half-sandwich Ru-based organometallic complexes with immunomodulatory response in melanoma treatments.

Rhodamine-modified Fluorescent Half-Sandwich Iridium and Ruthenium Complexes: Potential Application As Bioimaging and Anticancer Agents

In Vitro and In Vivo Antitumor Assay of Mitochondrially Targeted Fluorescent Half-Sandwich Iridium(III) Pyridine Complexes

Configurationally regulated half-sandwich iridium(III)-ferrocene heteronuclear metal complexes: Potential anticancer agents

Increasing Anticancer Activity with Phosphine Ligation in Zwitterionic Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes

Potent Half-Sandwich 16-/18-Electron Iridium(III) and Ruthenium(II) Anticancer Complexes with Readily Available Amine-Imine Ligands

Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp 2 -N/sp 3 -N Donor Ligands to Achieve Improved Anticancer Selectivity

In Vitro and In Vivo of Triphenylamine-Appended Fluorescent Half-Sandwich Iridium(III) Thiosemicarbazones Antitumor Complexes

Preparation and antitumor application of N -phenylcarbazole/triphenylamine-modified fluorescent half-sandwich iridium( iii ) Schiff base complexes

Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes

Anticancer application of half-sandwich iridium(III) ferrocene-thiosemicarbazide Schiff base complexes

Zwitterionic Iridium Complexes: Synthesis, Luminescent Properties, and Their Application in Cell Imaging.

Lysosomal Targeted Cyclometallic Iridium(III) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application

Novel lanthanide–polymer complexes for dye-free dual modal probes for MRI and fluorescence imaging

Rhodium(I) Complexes Containing the N^N^N-Chelating Ligand: Synthesis, Structure, and Biological Activity

Design, synthesis, cell imaging, and bioactivity assessment of novel rhodamine-pyrimidine nido- carborane derivatives as fluorescent anticancer agents

Potent half-sandwich Ru(II) N^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities

A Half-Sandwich Ruthenium(II) (N^N) Complex: Inducing Immunogenic Melanoma Cell Death in Vitro and in Vivo.

Anticancer Study on Ir III and Rh III Half-Sandwich Complexes with the Bipyridylsulfonamide Ligand

Imaging of a Clickable Anticancer Iridium Catalyst.

Fortuitous synthesis of unsaturated half-sandwich Ruthenium(II) complexes via solvent-involved rearrangement and their biological evaluation

Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance